The schizophrenia therapy market is mature and very crowded given the presence of numerous atypical and typical antipsychotic agents, including the continued genericization of key oral therapies, the availability of newer oral atypical antipsychotics (e.g., Otsuka\/Lundbeck\u2019s Rexulti and Allergan\u2019s Vraylar in the United States), and the intensifying competition between long-acting depot formulations of atypical antipsychotics. Indeed, to gain a foothold in the market, differentiation from already established therapies is a primary requirement for late-phase therapies\u2014including new atypical antipsychotics (Alkermes\u2019s ALKS-3831 and Lundbeck\u2019s Lu-AF35700), new depot formulations of current antipsychotics (e.g., Indivior\u2019s RBP-7000), the serotonin modulator (Acadia Pharmaceuticals\u2019 pimavanserin), and mixed neurotransmitter modulators (Intra-Cellular Therapies\u2019 lumateperone and Minerva Neurosciences\u2019 MIN-101). Meanwhile, the potential of early- to mid-stage therapies for negative symptoms and cognitive impairment associated with schizophrenia, symptoms on which drug developers are increasingly focusing, remains to be seen.<\/p>\n
QUESTIONS ANSWERED<\/p>\n
With aripiprazole\u2019s generic availability and it increasingly being used in earlier lines of therapy, what will be the commercial impact on the recently launched oral therapies Rexulti and Vraylar?
\nWhat factors drive and constrain the use of long-acting depot formulations of atypical antipsychotics? How is the competition heating up in this segment? Which long-acting injectables (LAIs) will be met with the greater commercial success in the United States, EU5, and Japan?
\nGiven the crowded and highly genericized market, what would key late-phase emerging therapies need to demonstrate in order to compete effectively?
\nWhat are the biggest areas of unmet need in the treatment of schizophrenia? Will emerging therapies address these needs over the course of the 2016-2026 forecast period?
\nPRODUCT DESCRIPTION<\/p>\n
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390879","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-schizophrenia","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390879\/revisions"}],"predecessor-version":[{"id":576805,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390879\/revisions\/576805"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}